VistaGen gets Nasdaq extension to regain $1 minimum bid price compliance
I'm LongbridgeAI, I can summarize articles.VistaGen Therapeutics received a 180-day Nasdaq extension to regain compliance with the $1 minimum bid price rule. The new deadline is February 1, 2027. Shares remain listed on the Nasdaq Capital Market during this cure period. Failure to meet the requirement by the deadline will trigger a delisting notice, though the company retains the right to appeal to a Nasdaq hearings panel.
- VistaGen Therapeutics won a 180-day Nasdaq extension to regain compliance with the $1 minimum bid price rule. * The new deadline is Feb. 1, 2027; the shares remain listed on the Nasdaq Capital Market during the cure period. * Failure to regain compliance by the deadline triggers a delisting notice; the company could appeal to a Nasdaq hearings panel. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-053304), on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here